Trials / Completed
CompletedNCT02946671
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Osaka University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety of preoperative combination therapy with KW-0761 (anti-CCR4) and ONO-4538 (anti-PD-1). To assess the behavior of immune cells in peripheral blood and tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mogamulizumab | Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered. |
| BIOLOGICAL | Nivolumab | Nivolumab (3.0 mg/kg) is administered. |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2020-03-01
- Completion
- 2020-03-01
- First posted
- 2016-10-27
- Last updated
- 2020-03-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02946671. Inclusion in this directory is not an endorsement.